Lyell Immunopharma (LYEL) EBT Margin (2020 - 2026)
Lyell Immunopharma (LYEL) posted EBT Margin of 5160800.0% for Q1 2026, down 114.0% sequentially from 2411550.0% in Q4 2025, and down 331961429.0% YoY from N/an in Q1 2025.
Lyell Immunopharma (LYEL) EBT Margin (2020 - 2026) Analysis & Trends
Lyell Immunopharma has reported EBT Margin for 7 years, with the latest figure at 5160800.0% in Q1 2026.
- Quarterly EBT Margin fell 331961429.0% year-over-year to 5160800.0% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 1501754.84% (down 4971484.0% YoY) and the FY2025 annual result came in at 795952.78%, up 38078493.0% from the prior year.
- EBT Margin declined to 5160800.0% in Q1 2026 per LYEL's latest filing, from 2411550.0% in the prior quarter.
- Over five years, EBT Margin peaked at 28.02% in Q4 2022 and troughed at 6279266.67% in Q3 2022.
- A 5-year average of 1759631.73% and a median of 995992.31% in 2024 frame the typical range for EBT Margin.
- The sharpest annual moves came in 2022 and 2023: EBT Margin sank 627706536 bps in 2022, then surged 599906667 bps in 2023.
- Over 5 years, EBT Margin stood at 28.02% in 2022, then sank by 8423430 bps to 2360315.38% in 2023, then plunged by 116 bps to 5100509.09% in 2024, then surged by 53 bps to 2411550.0% in 2025, then tumbled by 114 bps to 5160800.0% in 2026.
- According to Business Quant data, EBT Margin over the past three periods registered 5160800.0%, 2411550.0%, and 681120.0% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 34.77% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 18.33% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -94.22% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 12.09% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 13.77% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -2.67% |
| 10 | Lyell Immunopharma | 326.39 Mn | 326.39 Mn | - | -2,573,500.00% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2,573,500.00% |
| Mar 31, 2026 | -5,160,800.00% |
| Dec 31, 2025 | -2,411,550.00% |
| Sep 30, 2025 | -681,120.00% |
| Jun 30, 2025 | -1,443,337.50% |
| Mar 31, 2025 | -1,841,185.71% |
| Dec 31, 2024 | -5,100,509.09% |
| Sep 30, 2024 | -365,905.88% |
| Jun 30, 2024 | -995,992.31% |
| Mar 31, 2024 | -2,496,966.67% |
| Dec 31, 2023 | -2,360,315.38% |
| Sep 30, 2023 | -280,200.00% |
| Jun 30, 2023 | -336,318.52% |
| Mar 31, 2023 | -128,167.69% |
| Dec 31, 2022 | -28.02% |
| Sep 30, 2022 | -6,279,266.67% |
| Jun 30, 2022 | -363.66% |
| Mar 31, 2022 | -31,712.30% |
| Dec 31, 2021 | -6,248.12% |
| Sep 30, 2021 | -2,201.31% |